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Abstract
Background: Complicated skin and soft tissue infections (cSSTIs) occur frequently, but limited data do not allow
any consensus on an optimal treatment strategy. We designed this prospective, multicenter, observational study to
to explore the current epidemiology, treatment, and resulting clinical outcomes of cSSTIs to help develop strategies
to potentially improve outcomes.
Methods: From June 2008 to December 2009 we enrolled a pre-specified number of adults treated in 56 U.S.
hospitals with intravenous antibiotic(s) for any of the following cSSTIs: diabetic foot infection (DFI); surgical site
infection (SSI); deep soft tissue abscess (DSTA); or, cellulitis. Investigators treated all patients per their usual practice
during the study and collected data on a standardized form.
Results: We enrolled 1,033 patients (DFI 27%; SSI 32%; DSTA 14%; cellulitis 27%; mean age 54 years; 54% male), of
which 74% had healthcare-associated risk factors. At presentation, 89% of patients received initial empiric therapy
with intravenous antibiotics; ~20% of these patients had this empiric regimen changed or discontinued based on
culture and sensitivity results. Vancomycin was the most frequently used initial intravenous antibiotic, ordered in
61% of cases. During their stay 44% of patients underwent a surgical procedure related to the study infection,
usually incision and drainage or debridement. The mean length of stay was 7.1 days, ranging from 5.8 (DSTA) to
8.1 (SSI).
Conclusion: Our findings from this large prospective observational study that characterized patients with cSSTIs
from diverse US inpatient populations provide useful information on the current epidemiology, clinical
management practices and outcomes of this common infection.
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Keypoints: This large prospective observational study that characterized patients with cSSTIs from diverse US
inpatient populations provides useful information on the current epidemiology clinical management practices and
outcomes of this common infection.
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Background
Skin and soft tissue infections (SSTIs) encompass a
variety of conditions, are associated with substantial
morbidity, and account for a large percentage of infec-
tions requiring hospitalization [1,2]. Infections have gen-
erally been considered as complicated (cSSTIs) if they
required surgical procedures (in addition to antibiotic
therapy) or if they involved deeper subcutaneous tissue
(e.g., fascia or muscle) [1,2]. Recently, the U.S. Department
of Health and Human Services Food and Drug Adminis-
tration Center for Drug Evaluation and Research intro-
duced a new terminology for acute bacterial skin and
skin structure infections [3], but because this was after
we had completed our study we have retained the earlier
classification for this report. CSSTIs are now more chal-
lenging to manage, as the spectrum of causative patho-
gens is more complex and the prevalence of antibiotic
resistant microorganisms, especially methicillin-resistant
Staphylococcus aureus (MRSA), has increased [4,5].
While there is currently no clear consensus on how to
manage these infections, treatment virtually always
includes administering antibiotic therapy and often
requires concomitant drainage and debridement proce-
dures. The management approach depends on many
factors, including the infection type and severity, epide-
miologic setting, likely causative pathogens, and local
antibiotic resistance patterns [2,6-8]. Despite the frequent
occurrence of cSSTIs, our current understanding is lim-
ited about their clinical characteristics at presentation,
how they are treated in actual clinical settings, and what
the outcomes are of treatment.
Previously published controlled clinical studies of
cSSTIs have enrolled relatively homogeneous patient
populations, had strict inclusion and exclusion criteria
and protocol-defined treatment algorithms [9-13]. They
are efficacy trials, designed to determine whether an
intervention produces the expected result under ideal
circumstances. On the other hand, most published “real-
world” studies of cSSTIs are based on retrospective data
sources which often do not provide detailed information
on patient presentations, approaches to treatment or clin-
ical outcomes [14,15]. Observational studies are designed
to examine usual treatment patterns and everyday prac-
tices, optimally across a broad spectrum of patients and
health care settings, to provide complementary data to
those obtained in other study types.
The goal of this prospective observational study of
patients with cSSTIs was to explore the current epidemi-
ology, treatment, and resulting clinical outcomes of
these infections. A clearer understanding of the current
practice patterns in managing patients with cSSTIs in
usual clinical settings should help in the development of
strategies to improve the treatment of these common
and potentially severe infections.
Methods
We enrolled patients hospitalized between June 2008
and December 2009 in 56 U.S. hospitals that we selected
to include those of varying size, ownership status, aca-
demic affiliation, and geographic regions. We selected
investigators based on their experience working on the
inpatient service at each of these hospitals. An Institu-
tional Review Board approved the protocol for each site;
9 sites used a central ethical review board (Quorum
Review, Seattle, WA), while the rest used their local
Institutional Review Board and all enrolled patients
provided informed consent.
Study population
Patients aged ≥18 years were eligible for this study if
they were: hospitalized with signs and symptoms of
infection consistent with a diagnosis of diabetic foot
infection (DFI), surgical site infection (SSI), deep soft
tissue abscess (DSTA), or cellulitis, as defined in the
protocol; had an expected inpatient stay for treatment
of the study infection of ≥48 h; and, were treated with
intravenous antibiotic agents as the primary regimen
during the inpatient episode. Patients were excluded
from the study if they: had been treated with intravenous
antibiotic for >24 h prior to enrollment; were expected
to undergo amputation or complete resection of the
infected site; had any diagnosis of necrotizing soft tissue
infection, burn, gangrene, decubitus ulcer, animal or
human bites, known or suspected osteomyelitis, or
mediastinitis; were transferred from another hospital
within the previous 24 h; were pregnant; had any other
known or suspected condition that might jeopardize
their adherence to protocol; were employees of, or in an-
other study under, the local investigator or study hospital;
and were or wished to be simultaneously participating in
any other interventional clinical trial.
Our initial target was to enroll a total of 1,200 patients
from all the hospitals combined, with 300 patients in
each of the four infection types listed above. To achieve
this equal distribution of patients, we closed the enroll-
ment earlier for cellulitis, since we reached the targeted
number of patients sooner, and extended the enrollment
period for SSI and DFI. After the start of the study,
we reduced our target for enrollment for DSTA to 150
patients, in light of the November 2008 FDA Advisory
Committee discussion highlighting the limited role of
antibiotics in treating these infections [3,10].
Data collection
We developed a study protocol and standardized case
report forms (CRFs) and trained the investigators how to
use them. Investigators prospectively collected the
required data at the following times: study enrollment;
the end of intravenous antibiotic therapy; the end of
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hospitalization; during a telephone follow-up visit
28–35 days post-discharge from the hospital; and, be-
tween these events, as required. They submitted com-
pleted CRFs electronically to a centralized database; we
then rigorously reviewed them and queried the investi-
gators for any missing or unclear data.
Study measures
We collected information at the time of enrollment about
patient characteristics (e.g., age, gender, ethnicity, race,
and source of admission) and co-morbid conditions (e.g.,
chronic lung disease, diabetes, hepatic dysfunction, per-
ipheral vascular disease, renal insufficiency, and systemic
cancer). We defined healthcare-associated infections as
those occurring in patients who were: hospitalized during
the 6 months prior to the admission; residents of, or ad-
mitted from, a nursing home; in an immunosuppressed
state; recipients of any antibiotic during the 30 days prior
to the study infection; or, receiving dialysis.
We documented the clinical presentation of the infec-
tion, including the anatomic site, deepest involvement of
the wound, presence of any regional lymphadenopathy,
signs and symptoms of inflammation, presence of any
abscess, or break in the skin. We estimated wound
severity using wound measurements and various infection
parameters that comprise an infection scoring system pre-
viously developed and validated for DFIs. [16-22] We
reported the 5-item wound parameter subtotal, which is
identical for open and non-open wounds (range 0–15), as
well as the 8-item (range 3–43) and 10-item (range 3–49)
wound severity scores for those with an open wound at
the end of intravenous treatment. We reported a score
as “missing” if wound assessment parameters were
incomplete.
We recorded all treatments received for the study
infection throughout the hospital stay. This included
the initial intravenous antibiotic(s) administered, reasons
for their administration and discontinuation, and which
if any antibiotics were prescribed at discharge. We
recorded all surgical procedures performed related to the
study infection, and specifically noted those we consid-
ered as “source control” (i.e., incision and drainage, sur-
gical debridement, excision of wound, amputation).
The outcomes we captured included hospital mortality,
length of hospital stay (LOS), health-related quality of
life scores using EURO-Quality of Life Questionnaire
(EQ-5D) index (range 0–1) and EURO-Quality of Life
Visual Analog Score (EQ-VAS, range 0–100) [23], the
need for any surgical procedures, and clinical assessment
of the infection (resolved/cured, improved, unchanged,
or worsened, as measured at the end of intravenous anti-
biotic treatment based on investigator’s clinical judgment).
LOS excluded the number of days that discharge was
delayed due to a procedure not related to the study
infection.
Data analysis
We conducted descriptive analyses, both overall and by
infection type. For patients diagnosed with more than
one type of infection, we used the dominant one for clas-
sification. We report continuous variables with mean,
median and range, and summarize categorical variables
using frequencies and percentages.
Results
Baseline demographic characteristics
After making adjustments to the target number of
patients to ensure that we attained an adequate repre-
sentation of each infection type, 1,033 patients met the
criteria for inclusion in this analysis (Table 1), of whom
278 (26.9%) had DFI, 330 (31.9%) had SSI, 147 (14.2%)
had DSTA, and 278 (26.9%) had cellulitis. The overall
study population had a mean age of 54.2 years (median:
54.0; range 18–94), 45.9% were female, and 76.6% were
white. Patients with DSTA were younger (mean age 44),
more likely to be female (57.3%) and to be Hispanic
(14.3%), and less likely to be white (64.6%). About three-
quarters of the patients were admitted from the emer-
gency department (range 64–83%), and almost one-fifth
were admitted from the physician’s office (range 13–23%).
Clinical characteristics
Among the active co-morbid conditions at the time of
enrollment (Figure 1), diabetes was the most common in
each infection type, followed by peripheral vascular dis-
ease and renal insufficiency. As shown in Figure 2, 73.6%
of patients had at least one healthcare associated risk
factor, the most common of which were hospitalization
within the past 6 months and antibiotic use within the
past 30 days. Although by definition all SSI cases should
be healthcare-associated, we only identified 94.2% as
such based on our operational definition, which might
miss some cases where the related surgery was per-
formed in an outpatient setting or beyond 6 months.
Infection clinical presentation
The anatomic site varied by type of infection (Table 2),
but occurred most commonly on the foot (28.5%) and
lower leg (23.7%). The most common infection site was
the foot in DFI patients (87%), the abdomen in SSI
patients (29.7%), the lower leg in cellulitis patients
(49.6%), and other sites including the hand, arm, face,
buttocks in DSTA patients (70.%). In approximately half
of the patients, the deepest involvement of the infection
site was the subcutaneous tissue. Patients with cellulitis
had more infections involving only the epidermis/dermis
(43.2%) than those with other infection types. Regional
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lymphadenopathy was present in 11.0% of patients and
was more common among those with DSTA (21.1%).
About 90% of patients had erythema, tenderness, pain,
or local warmth, the severity of which was mostly mod-
erate (40-50%). Abscess, induration, tenderness, and pain
were more common and more severe among patients
with DSTA, while patients with cellulitis had more
severe erythema and local warmth. Overall, 66.0% of
patients had an open wound. We defined “fever” as a
temperature of ≥100.4°F (38°C); at baseline fever was
present in 85 (8.2%) of the 1033 patients on whom this
information was recorded: 8.6% of the patients with cel-
lulitis, 8.6% of those with a DFI, 12.2% of those with a
DSTA and 5.8% of those with a SSI. The mean 5-item
Table 1 Demographic characteristics of study population by infection type
Overall Diabetic foot
infection
Surgical site
infection
Deep soft
tissue abscess
Cellulitis
(N=1,033) (N=278) (N=330) (N=147) (N=278)
Age: mean (median, range) 54.2 (54.0, 18–94) 57.6 (57.0, 19–93) 54.9 (55.5, 18–92) 44.0 (43.0, 19–84) 55.5 (53.0, 19–94)
Female: N (%) 474 (45.9) 99 (35.6) 189 (57.3) 53 (36.1) 133 (47.8)
Ethnicity: N (%)
Hispanic/Latino 80 (7.7) 20 (7.2) 19 (5.8) 21 (14.3) 20 (7.2)
Not Hispanic/Latino 952 (92.2) 257 (92.4) 311 (94.2) 126 (85.7) 258 (92.8)
Missing 1 (0.1) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0)
Race: N (%)
White 790 (76.5) 196 (70.5) 270 (81.8) 95 (64.6) 229 (82.4)
Black 204 (19.7) 64 (23.0) 53 (16.1) 42 (28.6) 45 (16.2)
Asian 13 (1.3) 7 (2.5) 2 (0.6) 3 (2.0) 1 (0.4)
American Indian or Alaska Native 5 (0.5) 0 (0.0) 2 (0.6) 3 (0.7) 2 (0.7)
Native Hawaiian or Pacific Islander 20 (1.9) 10 (3.6) 3 (0.9) 6 (4.1) 1 (0.4)
Missing 1 (0.1) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0)
Admission source: N (%)
Nursing home 4 (0.4) 1 (0.4) 3 (0.9) 0 (0.0) 0 (0.0)
Emergency department 767 (74.2) 225 (80.9) 211 (63.9) 122 (83.0) 209 (75.2)
Physician’s office 188 (18.2) 37 (13.3) 77 (23.3) 20 (13.6) 54 (19.4)
Other 74 (7.2) 15 (5.4) 39 (11.8) 5 (3.4) 15 (5.4)
0%
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80%
100%
Chronic Lung Disease Diabetes Hepatic Dysfunction Peripheral Vascular 
Disease
Renal Insufficiency Systemic Cancer
Overall Diabetic Foot Infection Surgical Site Infection Deep Soft Tissue Abscess Cellulitis
Figure 1 Baseline Co-morbid Conditions of Study Population by Infection Type.
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wound score was 8.4 at baseline and decreased to 3.6 at
the end of treatment. The mean 8-item and 10-item
wound severity scores were 17.8 and 20.2 at baseline and
12.5 and 13.6 at the end of treatment.
Treatment patterns
The most commonly used classes of initial intravenous
antibiotic prescribed (Table 3) were glycopeptides (i.e.,
vancomycin) (61.0%), penicillins (37.4%), cephalosporins
(18.2%) and lincosamides (14.2%). These antibiotics were
administered for 2–3 days on average. Use of glycopep-
tides was highest in DSTA patients (74.1%), use of penicil-
lins, particularly those combined with beta-lactamase
inhibitors, was highest in DFI patients (50.4%), and use of
cephalosporins, particularly first-generation agents, was
higher in SSI (11.2%) and cellulitis (13.3%) patients than in
others. In 88.8% of patients, the investigators administered
initial intravenous antibiotic therapy as empiric treatment.
In most patients (85.8%), the initial intravenous antibiotic
administered was discontinued prior to their discharge.
The most common reasons for discontinuation were
either switching to another route or formulation (53.6%)
or improvement, resolution, or cure of the infection
(43.6%). Antibiotic was discontinued for 17.5% of patients
because culture results indicated that the initial intraven-
ous antibiotic was not needed, and for 4.1% because the
pathogen was not susceptible to the antibiotic agent.
Procedures and outcomes
A total of 41.2% of patients underwent surgical proce-
dures related to the study infection (Table 4), many of
which were performed on those with DSTA (68.0%).
Overall, 17.5% of patients had a source control pro-
cedure, with incision and drainage being the most
common (11.3%).
At the end of intravenous treatment, the infection
was classified as resolved/cured in only 8% of patients
but improved in 80.9%. Health-related quality of life at
baseline was similar across infection types, with a mean
EQ-5D index of 0.6 and mean EQ-VAS of 57.4. On aver-
age, EQ-5D index increased 0.1 from baseline to hospital
discharge, with a greater improvement among DSTA and
cellulitis patients. Mean change in EQ-VAS was 11.7,
with a greater improvement among DSTA patients. The
mean LOS was 7.1 days, ranging from 5.8 days for DSTA
patients to 8.1 days for SSI patients. Hospital mortality
was only 0.4%.
Discussion
We initiated this multicenter, prospective observational
study to learn about the current epidemiology, clinical
presentation, treatment and outcomes for patients with
cSSTIs. The study protocol did not recommend or
mandate any initial or subsequent interventions, but
CRFs recorded each of the local physicians’ management
0%
20%
40%
60%
80%
100%
Any Healthcare-
associated
Risk Factors
Hospitalization
within Past
6 Months
Resident of or 
Admitted from
Nursing Home
Immuno-
suppressed
State
Antiobiotic Use
in Past 30 Days
Receiving
Dialysis
Overall Diabetic Foot Infection Surgical Site Infection Deep Soft Tissue Abscess Cellulitis
Figure 2 Healthcare associated risk factors in the study population, by infection type.
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Table 2 Baseline clinical presentations of infection site, overall and by infection type
Overall Diabetic foot infection Surgical site infection Deep soft tissue abscess Cellulitis
(N=1,033) (N=278) (N=330) (N=147) (N=278)
Infection site (%)
Abdomen 11.8 0.0 29.7 6.1 5.4
Upper leg 6.8 0.0 12.1 9.5 5.8
Lower leg# 23.7 12.2 16.4 12.9 49.6
Foot 28.5 87.1 6.4 1.4 10.4
Other* 28.5 0.0 33.9 70.1 28.4
Missing 0.8 0.7 1.5 0.0 0.4
Deepest involvement: N (%)
Epidermis/dermis 274 (23.9) 79 (28.4) 55 (16.7) 20 (13.6) 120 (43.2)
Subcutaneous tissue 575 (55.7) 153 (55.0) 179 (54.2) 101 (68.7) 142 (51.1)
Fascial plane 115 (11.1) 30 (10.8) 56 (17.0) 18 (12.2) 11 (4.0)
Muscle 55 (5.3) 12 (4.3) 33 (10.0) 8 (5.4) 2 (0.7)
Missing 14 (13.6) 4 (14.4) 7 (2.1) 0 (0.0) 3 (1.1)
Regional adenopathy: N (%)
Present 114 (11.0) 23 (8.3) 20 (6.1) 31 (21.1) 40 (14.4)
Absent 901 (87.2) 252 (90.6) 299 (90.6) 114 (77.6) 236 (84.9)
Missing 18 (1.7) 3 (0.1) 11 (3.3) 2 (1.4) 2 (0.1)
Erythema: N (%)
Absent 73 (7.1) 20 (7.2) 38 (11.5) 8 (5.4) 7 (2.5)
Mild 218 (21.1) 57 (20.5) 102 (30.9) 26 (17.7) 33 (11.9)
Moderate 516 (50.0) 154 (55.4) 135 (40.9) 76 (51.7) 151 (54.3)
Severe 216 (20.9) 44 (15.8) 49 (14.8) 37 (25.2) 86 (30.9)
Missing 10 (1.0) 3 (1.1) 6 (1.8) 0 (0.0) 1 (0.4)
Abscess: N (%)
Absent 713 (69.0) 214 (77.0) 244 (73.9) 15 (10.2)$ 240 (86.3)
Mild 102 (9.9) 30 (10.8) 24 (7.3) 35 (23.8) 13 (4.7)
Moderate 160 (15.5) 25 (9.0) 43 (13.0) 72 (49.0) 20 (7.2)
Severe 46 (4.5) 6 (2.2) 11 (3.3) 25 (17.0) 4 (1.4)
Missing 12 (1.2) 3 (1.1) 8 (2.4) 0 (0.0) 1 (0.4)
Induration: N (%)
Absent 230 (22.3) 72 (25.9) 89 (27.0) 20 (13.6) 49 (17.6)
Mild 280 (27.1) 75 (27.0) 102 (30.9) 24 (16.3) 79 (28.4)
Moderate 390 (37.8) 105 (37.8) 99 (30.0) 73 (49.7) 113 (40.6)
Severe 120 (11.6) 22 (7.9) 33 (10.0) 30 (20.4) 35 (12.6)
Missing 13 (1.3) 4 (1.4) 7 (2.1) 0 (0.0) 2 (0.7)
Tenderness: N (%)
Absent 98 (9.5) 55 (19.8) 21 (6.4) 6 (4.1) 16 (5.8)
Mild 265 (25.7) 85 (30.6) 91 (27.6) 21 (14.3) 68 (24.5)
Moderate 445 (43.1) 108 (38.8) 147 (44.5) 63 (24.5) 127 (45.7)
Severe 213 (20.6) 27 (9.7) 64 (19.4) 57 (38.8) 65 (23.4)
Missing 12 (1.2) 3 (1.1) 7 (2.1) 0 (0.0) 2 (0.7)
Pain: N (%)
Absent 102 (9.9) 56 (20.1) 22 (6.7) 5 (3.4) 19 (6.8)
Mild 228 (22.1) 81 (29.1) 79 (23.9) 14 (9.5) 54 (19.4)
Moderate 425 (41.1) 97 (34.9) 142 (43.0) 62 (42.2) 124 (44.6)
Severe 268 (25.9) 41 (14.7) 82 (24.8) 66 (44.9) 79 (28.4)
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decisions. The prospective design of the study made it
possible to capture a more comprehensive patient profile,
including data on risk factors for healthcare-associated
infections, wound measurements, and infection para-
meters. These enabled us to score wound severity, to
clinically assess the infection, to note the reasons investi-
gators initiated and discontinued each agent, and to
evaluate quality of life measures. Furthermore, we en-
rolled a large number of patients with varied types of
infections admitted to hospitals representing a wide-
range of types of institutions and geographic regions.
Thus, these data are likely to reflect usual current clinical
practice for managing cSSTIs in hospitalized patients in
the US.
Our study showed that, among the 1,033 patients en-
rolled, 73.5% had a healthcare-associated infection. This
is nearly identical to the 73.6% reported in a single-
center retrospective cohort study of patients hospitalized
with cSSTIs [15]. Compared to our study, their criteria
for defining healthcare-associated infection used a longer
time frame for previous hospitalization (1 year versus
6 months) and previous antibiotic use (90 days versus
30 days) and did not include immunosuppressed state as
a criterion. This rate of healthcare associated infection is
considerably higher, however, than the 27% reported in a
recent retrospective cohort study of more than 12,000
patients hospitalized with skin, soft-tissue, bone or joint
infection [24]. This difference could be attributed to that
study including bone and joint infections, and using a
definition of healthcare associated infection with a sub-
stantially shorter timeframe for previous hospitalization
compared with ours (30 days versus 180 days) and that
did not include previous antibiotic treatment, a criterion
met by 47.6% of our patients. Physicians treating patients
with cSSTI may find the high prevalence rate of
healthcare-associated infections noted in this study to be
clinically important, as previous studies [15,24] have
reported that these patients had longer lengths of stay,
higher mortality, and higher hospital costs.
Our evaluation of initial antibiotic treatment revealed
that vancomycin was used considerably more often (in
61.0%) than has been reported in previous studies. Two
retrospective multicenter studies performed in the past
decade, both of which used an inpatient claims database,
eported initial treatment with vancomycin in 17.6%
and 27.8% of cSSTI patients, respectively [14,25]. The
much higher use of vancomycin in our study is likely
attributable to the steep rise in the prevalence of
MRSA as a pathogen in cSSTIs over the past several
years [26]. It is noteworthy that the initial intravenous
therapy selected was discontinued in over a fifth of
patients because it was either not needed or inappropriate.
Also of note is that a substantial percentage of patients
were treated with relatively broad-spectrum agents that
are typically used to cover gram-negative bacilli (e.g.,
fluoroquinolones, 3rd generation cephalosporins, amino-
glycosides), which is probably unnecessary in most cases
of cSSTI.
The mean LOS we observed in this study is longer
than might be observed in some practices; this is prob-
ably related to the fact that we enrolled patients with
more severe infections as they needed to be hospitalized
Table 2 Baseline clinical presentations of infection site, overall and by infection type (Continued)
Missing 10 (1.0) 3 (1.1) 5 (1.5) 0 (0.0) 2 (0.7)
Local warmth: N (%)
Absent 94 (9.1) 22 (7.9) 53 (16.1) 9 (6.1) 10 (3.6)
Mild 342 (33.1) 105 (37.8) 136 (41.2) 31 (21.1) 70 (25.2)
Moderate 478 (46.3) 126 (45.3) 109 (33.0) 85 (57.8) 158 (56.8)
Severe 105 (10.2) 21 (7.6) 24 (7.3) 22 (15.0) 38 (13.7)
Missing 14 (1.4) 4 (1.4) 8 (2.4) 0 (0.0) 2 (0.7)
Open wound: N (%)
Yes 682 (66.0) 255 (91.7) 249 (75.5) 78 (53.1) 100 (36.0)
No 343 (33.2) 21 (7.6) 76 (23.0) 69 (46.9) 177 (63.7)
Missing 8 (0.8) 2 (0.7) 5 (1.5) 0 (0.0) 1 (0.4)
Wound score^: mean (median, range)
5-item 8.4 (8.0, 0–15) 7.5 (7.5, 0–15) 7.8 (8.0, 0–15) 10.0 (10.0, 0–15) 9.3 (9.0, 2–15)
8-item 17.8 (17, 4–43) 15.7 (15, 4–37) 19.5 (18, 5–43) 20.8 (20, 4–39) 17.0 (16, 8–38)
10-item 20.2 (19, 5–46) 17.8 (18, 5–41) 22.5 (21, 8–46) 23.5 (22.5, 7–43) 18.6 (17, 8–41)
#For a diabetic foot infection, infection site would be on the ankle or below.
*Other infection sites included face, scalp, neck, chest, pelvis/genitals, back, buttocks, hand, upper arm, and lower arm.
$Although DSTA was the dominant diagnosis, the abscess was not present at baseline for some patients (i.e., the abscess developed during hospitalization).
^Note: The 5-item wound parameter was estimated for both open and non-open wounds, but was available only for a portion of the total patient population
(98.5%). 8-item and 10-item wound severity scores were calculated only among patients with an open wound, but was available only for a portion of patients
(83%).
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for at least 48 h. Our LOS is, however, similar to those
previously reported in patients hospitalized for cSSTIs
[15,24,27]. Despite differences in patient population, the
overall mean LOS in our study (7.1 days, ranging from
5.8 to 8.1 days) was similar to that reported by Lipsky
et al. (7.3 days, ranging from 5.1 to 8.9 days depending
on infection type and whether or not the infection was
complicated) [24]. The LOS for patients with cellulitis or
SSI, the two infection types examined in our study that
were also included individually in the Lipsky study [24],
were slightly higher in our study, probably because many
of our patients would have been considered to have a
complicated infection. The LOS found in our study is
also similar to that found by Zilberberg et al. [15],
(9.4 days for patients with healthcare associated infec-
tion and 5.5 days for community associated infection)
and Edelsberg et al. [14] (5.2 days for those successfully
treated and 10.6 days for those who failed treatment).
Table 3 Antibiotic treatment patterns by infection type
Overall Diabetic foot
infection
Surgical site
infection
Deep soft
tissue abscess
Cellulitis
(N=1,033) (N=278) (N=330) (N=147) (N=278)
Initial intravenous antibiotics: N (%) *
Glycopeptidesa 630 (61.0) 167 (60.1) 186 (56.4) 109 (74.1) 169 (60.4)
Penicillinsb 386 (37.4) 141 (50.7) 101 (30.6) 53 (36.1) 91 (32.7)
Beta-lactamase -inhibitorsc 380 (36.8) 140 (50.4) 98 (29.7) 53 (36.1) 89 (32.0)
Beta-lactamase -resistantd 7 (0.7) 1 (0.4) 3 (0.9) 0 (0.0) 3 (1.1)
Non-beta-lactamase inhibitorse 7 (0.7) 2 (0.7) 1 (0.3) 0 (0.0) 4 (1.4)
Cephalosporinsf 188 (18.2) 41 (14.8) 64 (19.4) 15 (10.2) 68 (24.5)
First-generation 90 (8.7) 13 (4.7) 37 (11.2) 3 (2.0) 37 (13.3)
Third-generation 69 (6.7) 18 (6.5) 15 (4.5) 11 (7.5) 25 (9.0)
Fourth-generation 27 (2.6) 9 (3.2) 13 (3.9) 0 (0.0) 5 (1.8)
Lincosamidesj 147 (14.2) 31 (11.2) 38 (11.5) 25 (17.0) 53 (19.1)
Fluoroquinolonesk 90 (8.7) 28 (10.1) 35 (10.6) 11 (7.5) 16 (5.8)
Daptomycin 28 (2.7) 5 (1.8) 13 (3.9) 4 (2.7) 6 (2.2)
Nitroimidazole derivativesm 27 (2.6) 7 (2.5) 14 (4.2) 1 (0.7) 5 (1.8)
Other Antibiotics n 26 (2.5) 8 (2.9) 8 (2.4) 4 (2.7) 6 (2.2)
Treatment duration of the most common initial intravenous antibiotics: mean (median, minimum-maximum)
First-generation cephalosporins 2.5 (1.7, 0–27) 1.5 (1.7, 0–3) 3.2 (1.7, 0–27) 1.6 (1.5, 0–3) 2.2 (1.5, 0–12)
Glycopeptides 3.2 (2.6, 0–24) 3.7 (2.7, 0–24) 3.1 (2.6, 0–16) 2.8 (2.6, 0–11) 3.0 (2.7, 0–14)
Lincosamides 2.2 (1.6, 0–10) 1.9 (1.2, 0–8) 2.5 (1.5, 0–10) 2.3 (2.3, 0–7) 2.1 (1.7, 0–9)
Penicillins (beta-lactamase-inhibitors) 3.4 (2.6, 0–36) 3.8 (2.8, 0–24) 3.9 (2.9, 0–36) 2.4 (2.1, 0–7) 2.8 (2.4, 0–13)
Reason for administration of initial intravenous antibiotics: N (%)*
Empiric treatment prior to culture test results 917 (88.8) 243 (87.4) 292 (88.5) 137 (93.2) 245 (88.1)
Not responding to previous antibiotic
treatment
42 (4.1) 6 (2.2) 13 (3.9) 6 (4.1) 17 (6.1)
Other 64 (6.2) 13 (4.7) 24 (7.3) 6 (4.1) 21 (7.6)
Reason for discontinuation of initial antibiotics: N (%)* 886 232 271 136 247
Switched to another route/formulation^ 475 (53.6) 108 (46.6) 147 (54.2) 82 (60.3) 138 (55.9)
Infection improved, resolved, or cured^ 386 (43.6) 105 (45.3) 99 (36.5) 62 (45.6) 120 (48.6)
Culture results indicate this antibiotic agent
not needed
155 (17.5) 43 (18.5) 56 (20.7) 32 (23.5) 24 (9.7)
Pathogen not susceptible to this antibiotic
agent^
36 (4.1) 8 (3.4) 19 (7.0) 3 (2.2) 6 (2.4)
*Not mutually exclusive.
^Percentages reported based on the number of patients who discontinued.
aIncludes vancomycin; bIncludes c, d, e below; cIncludes amoxi-clavulanico (amoxicillin, clavulanic acid), clavucar (clavulanic acid, ticarcillin), duocid (ampicillin,
sulbactam), piperacillin w/tazobactam; dIncludes dicloxacillin, nafcillin, oxacillin, piperacillin; eIncludes amoxicillin, ampicillin, benzylpenicillin; fIncludes g, h, i below;
gIncludes cefadroxil, cefalexin, cefazolin; hIncludes cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftriaxone; iIncludes cefepime; jIncludes clindamycin; kIncludes
ciprofloxacin, levofloxacin, moxifloxacin; lIncludes daptomycin, linezolid; mIncludes metronidazole; nIncludes linezolid, tigecycline, aztreonam, azithromycin,
erythromycin, rifampicin, rifaximin, doxycycline, minocycline.
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The in-hospital mortality rate in the overall cohort
in this study (0.4%) is, however, considerably lower
than the rates reported in the literature (0.8%-5.2%)
[14,15,24,27,28]. This could be related to differences in
patient populations, infection types or severity, or how
the infections were managed.
Our study has several limitations. First, there is a pos-
sibility of selection bias in the patients enrolled or hos-
pitals selected, notwithstanding our considerable efforts
to minimize this by establishing a priori definitions and
standardized data collection procedures. Secondly, we
did not recognize the need to provide the investigators
with specific enough criteria to identify DFI or SSI until
after patient enrollment had begun. Initially, we intended
for the investigators to use their discretion when enrolling
patients. While using this method would have added to
the naturalistic design of the study and resulted in enroll-
ment of a more heterogeneous population, several sites
asked us questions about what constituted a DFI or SSI.
Thus, we sent out clarification to all the sites on how to
define these infection types (see the appendix). Third,
although the data from this study underwent a rigorous
review and query process, the data accuracy and com-
pleteness ultimately depended on the investigators at
the study sites. To minimize this problem, we made
efforts to sign up experienced clinicians and trained them
on data collection in advance of the study. Fourth, clin-
ical outcome was based on the investigators’ subjective
assessment and not on a change in the wound score or
microbiological response at the end of therapy. This was
necessary, as there are no agreed upon criteria for the
wound score and the presence and resolution of cSSTIs are
based on clinical (not microbiological) criteria. Finally,
our findings may not be generalizable to non-hospitalized
patients, to patients hospitalized in other countries, to other
types of cSSTIs not included in our study, or to patients
who had conditions that were excluded from our study.
Strengths of this study include the prospective observa-
tional design, the variety of hospital types, the training of
the investigating clinicians, the attempt to define types of
cSSTIs, the development of standardized CRFs, the use of
a validated wound scoring system and the large number of
patients enrolled.
Conclusions
This multicenter, prospective observational study of
patients with cSSTIs was designed to explore the current
epidemiology, treatment, and resulting clinical outcomes of
patients hospitalized with these infections. During an 18
month period we enrolled 1033 patients. Almost 3/4ths of
patients had at least one healthcare associated risk factor.
Infections of the lower extremity comprised over half the
cases and two-thirds has an open wound. In almost 90% of
cases antibiotic therapy was initially an empiric intravenous
agent, the most common of which was vancomycin. A sub-
stantial percentage of the patients were treated with
Table 4 Surgical procedures performed and patient outcomes by infection type
Overall Diabetic foot
infection
Surgical site
infection
Deep soft
tissue abscess
Cellulitis
(N=1,033) (N=278) (N=330) (N=147) (N=278)
Surgical procedures related to study infection: N (%) 426 (41.2) 123 (44.2) 148 (44.8) 100 (68.0) 55 (19.8)
For source control: N (%) 181 (17.5) 56 (20.1) 48 (14.5) 56 (38.1) 21 (7.6)
Incision and drainage 117 (11.3) 25 (8.9) 29 (8.8) 47 (32.0) 16 (5.8)
Surgical debridement 41 (3.9) 11 (3.9) 18 (5.5) 8 (5.4) 4 (1.4)
Excision of wound 5 (0.4) 3 (1.1) 0 (0.0) 1 (0.7) 1 (0.4)
Amputation 18 (1.7) 17 (6.1) 1 (0.3) 0 (0.0) 0 (0.0)
Clinical assessment: N (%)
Resolved/cured 82 (7.9) 22 (7.9) 15 (4.6) 12 (8.2) 33 (11.9)
Improved 836 (80.9) 213 (76.6) 274 (83.0) 131 (89.1) 218 (78.4)
Unchanged 32 (3.1) 10 (3.6) 13 (3.9) 0 (0.0) 9 (3.2)
Worsened 6 (0.6) 3 (1.1) 2 (0.6) 0 (0.0) 1 (0.4)
Missing 77 (7.5) 30 (10.8) 26 (7.9) 4 (2.7) 17 (6.1)
Quality of life^
Change in EQ-5D Index at discharge: mean
(median, range)
0.1 (0.1, -0.8-0.9) 0.1 (0.1, -0.8-0.9) 0.1 (0.1, -0.7-0.9) 0.2 (0.2, -0.3-0.7) 0.2 (0.1, -0.7-0.8)
Change in EQ-VAS at discharge: mean (median, range) 11.7 (10, -93-100) 11.4 (10, -93-92) 11.5 (10, -55-90) 13.7 (10, -45-100) 11.1 (10, -50-85)
Length of stay: mean (median, range) 7.1 (5, 1–55) 7.6 (6, 1–26) 8.1 (6, 1–55) 5.8 (5, 2–31) 6.0 (5, 1–35)
Hospital mortality: N (%) 4 (0.4) 2 (0.7) 2 (0.6) 0 (0.0) 0 (0.0)
^Note: Quality of life scores were calculated only for a portion of the total patient population with available data (99.4% for EQ-5D Index at baseline, 89.7% for
change in EQ-5D Index at discharge, 99.3% for EQ-5D VAS at baseline, and 89.5% for change in EQ-5D VAS at discharge).
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unnecessarily broad-spectrum agents. Empiric antibiotics
were discontinued in about 1/5th of patients because cul-
ture results indicated they were not needed or the patho-
gen was not susceptible to the selected agent. Over 40% of
patients underwent some form of surgical treatment. At
the end of therapy infection was improved or resolved in
almost 90% of patients. Because of the study design these
data likely reflect usual current clinical practice for man-
aging cSSTIs in hospitalized patients in the US. This study
provides useful information on the current epidemiology
and clinical management practices and outcomes of hospi-
talized patients with cSSTIs.
Appendix
Appendix: clarification of DFI and SSI definitions*
In order for a patient to be enrolled as a diabetic foot
infection (DFI) patient, they were required to meet all
of the following 3 conditions:
 Have a history of diabetes mellitus
 Have an infection on or below the ankle
 Have a break (i.e., ulcer) in the epidermis where the
infection started (“You must be able to answer “yes”
to “open wound” on the Baseline Characteristics of
Open Wound assessment)
 Have a purulent discharge or at least two of the
following (on the Baseline Signs and Symptoms of
Inflammation assessment):
○ Erythema
○ Pain
○ Tenderness
○ Local warmth
○ Induration
In order for a patient to be enrolled as a surgical site
infection (SSI) patient, they were required to meet all of
the following 3 conditions:
 Have an infection that occurred within 30 days after
an operation
 Have an infection that involves only skin or
subcutaneous tissue at the incision site
 Have at least one of the following:
 Purulent drainage, with or without laboratory
confirmation, from the surgical incision
 Organisms isolated from a culture of an aseptically
obtained specimen of wound fluid or tissue from the
surgical incision site
 At least two of the following signs or symptoms of
infection: pain or tenderness, localized swelling,
redness, or warmth
 Diagnosis of surgical incisional infection by the
operating surgeon or attending physician
 An abscess or other evidence of infection involving
the surgical site found on direct examination, during
reoperation, or by histopathologic or imaging
examination
The following conditions were not to be reported as
SSI:
 Stitch abscess (minimal inflammation and discharge
confined to the points of suture penetration)
 Infection of an episiotomy or newborn circumcision
site
 Infected burn wound or infected stab or traumatic
wound
*These specific guidelines for DFI and SSI patients
were issued June 25, 2009. Following database lock, it was
discovered that of the 278 enrolled DFI patients, 23 were
not indicated as having an open wound. 19 of these were
enrolled prior to the June 25, 2009 guideline memo. None
of these 23 DFI patients were excluded from analyses on
the grounds of their not having an open wound.
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